



# Canostix GmbH

A low-cost multi-cancer blood test to detect the most common cancers at the primary care level.

<b>Area</b>	Diagnostics
<b>Headquarter</b>	Berlin, Germany
<b>Countries of operation</b>	India
<b>Founding year</b>	2018
<b>Status</b>	Prototype


<b>Incubator</b>	N/A
<b>Awards</b>	N/A
<b>Patents</b>	PCT/EP2016/078406
<b>Revenue (last yr)</b>	N/A
<b>Funds raised</b>	€230k
<b>Currently raising:</b>	€850k

## Summary

Canostix aims to beat cancer simply by diagnosing it so early that it can be already cured today. We achieve this by developing a blood-based early detection test that combines vibrational spectroscopy and machine learning. Starting with the five most common cancers covering 50% of all cancer cases we create a constantly evolving software solution that upgrades available hardware into top-of-the-line screening machines. This is done through a one-of-a-kind collaboration with leading Indian research institutes which enables us to fast-track clinical translation. Our goal is to introduce an affordable multi-cancer screening test at the primary care level that will result in less invasive treatments ultimately saving billions of dollars and millions of lives.

## USE OF FUNDS

■ Product Dev ■ Legal & other ■ Staff ■ Studies



## Interested? Get in touch

✉ [greg@clab.ventures](mailto:greg@clab.ventures)  
<http://canostix.com/>

